Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities

This article was originally published in The Pink Sheet Daily

Executive Summary

Because regulators and the market have become less accepting of follow-on compounds, the Japanese pharma plans to invest in first-in-class science, pursuing best-in-class opportunities only when it sees a substantial unmet medical need.

You may also be interested in...



ROCKET AF: Positive Results For Xarelto, But A Few Chinks In The Armor

Rivaroxaban misses two bleeding safety measures, and debate heats up on whether it showed superior efficacy against warfarin.

Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE

TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin

Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup

TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel